Towards evidence-based response criteria for cancer immunotherapy.
Where this comes from
- Record sourced from PubMed, PMID 37225715.
- Also identified by DOI 10.1038/s41467-023-38837-3 and PMC identifier 10209139.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.
Medical subject headings
- Neoplasms